Display Settings:

Format

Send to:

Choose Destination
We are sorry, but NCBI web applications do not support your browser and may not function properly. More information
    Nan Fang Yi Ke Da Xue Xue Bao. 2006 Aug;26(8):1206-8.

    [Clinical observation of target-controlled remifentanil infusion combined with propofol and doxapram in painless artificial abortion].

    [Article in Chinese]

    Source

    Department of Anesthesiology, Conghua Central Hospital, Conghua 510900, China. tanzm_526@163.com

    Abstract

    OBJECTIVE:

    To observe the impacts of doxapram on anesthetic efficacy and respiratory and circulatory functions during anesthesia with remifentanil given by target-controlled infusion (TCI) combined with propofol in painless artificial abortion.

    METHODS:

    A total of 120 ASA I women requiring voluntarily painless artificial abortion were randomized into two equal groups. One group was given remifentanil by TCI at 2 ng/ml and propofol 1mg/kg (group I), and the other given remifentanil by TCI, propofol, and doxapram 0.6 mg/kg (group II). The anesthetic efficacy and respiratory and circulatory suppression during anesthesia were observed.

    RESULTS:

    Both of the two groups showed satisfactory anesthetic efficacy with comparable the BIS values (P>0.05). No significant difference was noted in the induction time and awaking time between the two groups (P>0.05), but group I had more serious respiratory and circulatory depression than group II (P<0.05).

    CONCLUSION:

    Doxapram may attenuate respiratory and circulatory depression during anesthesia with remifentanil given by TCI combined with propofol in painless artificial abortion, and provide comparable anesthetic efficacy.

    PMID:
    16939923
    [PubMed - indexed for MEDLINE]
    Free full text

      Supplemental Content

      Icon for SOUTHERN MEDICAL UNIVERSITY

      Save items

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk